MANKIND2,246.00

Mankind Pharma Ltd.

· Pharma & Health
₹ CrorePeersSUNPHARMACIPLATORNTPHARMLAURUSLABSBIOCONALKEMLUPINGLENMARKMcap ₹92,715 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Inventory Days (DIO)305.91379.00342.10342.10
Receivable Days (DSO)29.9646.0044.2144.21
Payable Days (DPO)217.20205.17213.98205.09
Cash Conversion Cycle (days)118.67219.83172.33181.22
Working Capital Turnover2.288.0822.5823.30
Asset Turnover0.860.440.510.51
Cash Conversion (CFO/Net Income)1.111.201.611.61
CFO/EBITDA0.850.800.860.86
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.